Navigation Links
Pixantrone Increases Progression-Free Survival by 81% Compared to Standard Chemotherapeutic Agents in Phase III Relapsed Aggressive non-Hodgkin's Lymphoma Trial
Date:1/27/2009

SEATTLE, Jan. 28 /PRNewswire-FirstCall/ -- Cell Therapeutics (CTI) (Nasdaq and MTA: CTIC) announced today preliminary progression-free survival (PFS) results from its pivotal phase III EXTEND (PIX301) trial of pixantrone that show patients with advanced, relapsed aggressive non-Hodgkin's lymphoma (NHL) treated with pixantrone experienced a statistically significant improvement in median progression-free survival, compared with other single-agent chemotherapeutic agents (4.7 months vs. 2.6 months, p < 0.01, pixantrone vs. standard chemotherapy) based on an intent to treat analysis. PFS was a prospectively defined secondary endpoint in the study.

"We always believed the effectiveness of pixantrone would translate into a meaningful difference for patients with relapsed aggressive NHL and these dramatic and significant differences in PFS in this tough to treat group of patients provides that evidence," stated James A. Bianco, M.D. Chief Executive Officer of CTI. "Pixantrone is the first agent in this patient population to demonstrate a significant and meaningful PFS advantage. We believe these data will support a priority review designation on our New Drug Application (NDA) once we share them with the Food and Drug Administration (FDA)."

The Company had previously announced that its pivotal phase III (PIX 301) EXTEND trial had achieved its primary endpoint with patients randomized to treatment with pixantrone achieving a significantly higher rate of confirmed (CR) and unconfirmed complete remissions (CRu) compared to patients treated with standard chemotherapy (14/70 (20.0%) for pixantrone arm compared to 4/70 (5.7%) for the standard chemotherapy arm, p = 0.02) with no patients in the standard chemotherapy arm achieving a confirmed complete remission. Additionally, pixantrone treatment also significantly increased the overall response rate (CR/CRu+PR) (26/70 (37.1%) for pixantrone arm compared to 10/70 (
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
2. Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting
3. Pixantrone Shows Activity in a Preclinical Study of Experimental Autoimmune Myasthenia Gravis (EAMG)
4. Pixantrone to be Studied in Phase I/II Trial for Aggressive Multiple Sclerosis
5. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
6. Cell Therapeutics Announces Study Data Set Cut-off for Phase III Pivotal Pixantrone (301) Trial
7. Cell Therapeutics Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint
8. Pixantrone Pre-NDA Communication from FDA Provides Cell Therapeutics Basis to Begin Rolling NDA Submission
9. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
10. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
11. Demand for VScan Dengue Fever Test Kits Increases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... , July 31, 2014  Today, ... a new extension to its PageCenterX ® ... software is designed to provide downtime reporting capabilities ... outages. LRS is releasing the product for general ... environment, EMR applications experience outages for a variety ...
(Date:7/31/2014)... CITY, Calif. , July 31, 2014  Genomic Health, ... company will host a conference call and webcast on Thursday, ... second quarter 2014 financial results.  The call and webcast will ... market close. Conference Call Details To access the ... Time via phone, please dial (877) 303-7208 from ...
(Date:7/31/2014)... 31, 2014 Nutrastar International Inc. (OTCQB: NUIN; ... of premium branded consumer products, including commercially cultivated Cordyceps ... today announced the signing of its first distributor for ... to Hubei Province ... China . The contract with ...
Breaking Medicine Technology:LRS Announces Downtime Reporting Solution for Healthcare 2Genomic Health to Announce Second Quarter 2014 Financial Results and Host Conference Call on Thursday, August 7, 2014 2Genomic Health to Announce Second Quarter 2014 Financial Results and Host Conference Call on Thursday, August 7, 2014 3Genomic Health to Announce Second Quarter 2014 Financial Results and Host Conference Call on Thursday, August 7, 2014 4Nutrastar Signs First Distributor for New Cordyceps Powder Solution Product, Expands Reach to Central China 2Nutrastar Signs First Distributor for New Cordyceps Powder Solution Product, Expands Reach to Central China 3Nutrastar Signs First Distributor for New Cordyceps Powder Solution Product, Expands Reach to Central China 4
... March 5 A study published by Deborah ... the Journal of Drugs in Dermatology ... resurfacing technologies, specifically, the SmartXide DOT(TM) laser. DOT utilizes ... for rapid healing, less downtime and profound results. Dr. ...
... Complications Reported With Coronary DeviceDOYLESTOWN, Pa., March 4 ... in February by completing the enrollment of 30 ... clinical trial for the vProtect(TM) Luminal Shield, conducted ... Shield successfully crossed all target lesions and was ...
Cached Medicine Technology:New Study Published in the Journal of Drugs in Dermatology Finds DOT Microablative CO2 Laser Optimum for Skin Rejuvenation 2Prescient Medical Achieves Milestones in Clinical Studies of vProtect(TM) Luminal Shield 2
(Date:7/31/2014)... NY (PRWEB) July 31, 2014 ... H2 2014, provides an overview of the Brain ... information on the therapeutic development for Brain Cancer, ... assessment by drug target, mechanism of action (MoA), ... with latest updates, and featured news and press ...
(Date:7/31/2014)... July 31, 2014 Much of the liver,s metabolic ... body clock and UC Irvine researchers have now ... The study, published online today in Cell , ... metabolism and points the way to more focused drug ... obesity and diabetes. , Paolo Sassone-Corsi, UCI,s Donald Bren ...
(Date:7/31/2014)... The virus that causes cold sores -- herpes simplex type ... according to a new study. Researchers in Australia ... infected with the virus. This explains why some people with ... them only occasionally. The authors said the findings could lead ... when the disease was dormant, it was a truce. It ...
(Date:7/31/2014)... 31, 2014 i2i Systems announced today ... Inc. (SAS) to provide a robust patient referral ... SAS is one of the largest independent software companies ... than 40,000 patients are seen annually in its on-site ... delivering primary care, providers at the SAS HCC refer ...
(Date:7/31/2014)... Over the past five years, the ... the estimated 151 million individuals that have required some ... of Ophthalmology (AAO). According to a Consumer Reports National ... vision correction surgery, a large share of consumers have ... medical procedure was to eliminate the use of glasses ...
Breaking Medicine News(10 mins):Health News:Global Brain Cancer Market Size, Share, Analysis, Trends and Forecasts 2014 2Health News:Global Brain Cancer Market Size, Share, Analysis, Trends and Forecasts 2014 3Health News:Global Brain Cancer Market Size, Share, Analysis, Trends and Forecasts 2014 4Health News:Strict genomic partitioning by biological clock separates key metabolic functions 2Health News:Cold Sore Virus Active Without Symptoms, Study Finds 2Health News:SAS Selects i2i Systems for Health Care Center Patient Referral Database 2Health News:SAS Selects i2i Systems for Health Care Center Patient Referral Database 3Health News:Eye Surgery Clinics in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Eye Surgery Clinics in the US Industry Market Research Report from IBISWorld Has Been Updated 3
... , , , ... e-Zassi.com(TM), an online decision support software system, integrated business ... has partnered with Medical Development Group (MDG), a medical device ... agreement, MDG will provide access to the e-Zassi platform to ...
... Aug. 12 Hank Oprinski, the CEO at Cap ... tour to inform corporations, chambers of commerce, golfing communities, economic clubs, universities ... , What did all the following businessmen have ... Tiger Woods) , Merv Griffin (TV Producer) , Tom Witter (Dean/Witter/Reynolds) , ...
... , , , ... today that its CardioVasc Advantage(TM) Vascular Reconstruction Device has been ... , "The technology of the Advantage VRD ... noted company Chairman, Eric P. Milledge. "The technical platform behind ...
... , , , ... create expensive home health care costs. Poorly designed mobility aids or ... issue only part of the need is addressed which creates mobility ... alleviated if mobility issues were detected and properly addressed. , ...
... , , LONDON, Aug. ... optimal and efficient way and, at the same time, adhere ... pharmacovigilance tools and technologies. , , (Logo: ... Frost & Sullivan ( http://www.healthcareIT.frost.com ), World Pharmacovigilance Markets ...
... ... A GPS navigation device allows you to most accurately ... above the Earth’s surface - instantly. This multi-perspective triangulation clearly leads ... performance measurement system incorporates a number of key vital signs from ...
Cached Medicine News:Health News:Medical Development Group Partners with e-Zassi.com(TM) to Provide Members Access to Exciting New Software Tool 2Health News:Medical Development Group Partners with e-Zassi.com(TM) to Provide Members Access to Exciting New Software Tool 3Health News:September is Prostate Cancer Awareness Month 2Health News:Nfocus Neuromedical Obtains CE Approval for New Vascular Reconstruction Device 2Health News:Expensive Health Care: Undetected, Unmet Mobility Needs Creating Boomer & Senior Health Care Costs 2Health News:Frost & Sullivan: Outsourcing/Offshoring Environment Possesses Considerable Potential for Pharmacovigilance Market 2Health News:Frost & Sullivan: Outsourcing/Offshoring Environment Possesses Considerable Potential for Pharmacovigilance Market 3Health News:Utilizing GPS-like Measurement Precision To More Accurately Determine Overall Performance 2Health News:Utilizing GPS-like Measurement Precision To More Accurately Determine Overall Performance 3
... MDS display system provides maximum impact for ... This unique approach to displaying frames allows ... and create appealing, flexible and eye-catching displays. ... and your patients are motivated. Removable holders. ...
A pre-assembled, hexagonal, revolving tower display with two round 19.75" in diameter adjustable shelves. Enjoy 3.5 square feet of elegant shelf space for your products....
A pre-assembled, rectangular shadow box/wall hanging display. It have 3 adjustable shelves with tempered glass, four 50 watt halogen top lights, laminated deck, dust resistant and electrical cord wit...
Classic is proud to provide top-quality vision eyewear to physicians, health maintenance organizations (HMOs), and numerous state and federal government programs. Classic Laboratory produces over 150...
Medicine Products: